Nasal vaccination with Vaxinano's nanoparticles against flu virus inhibits virus transmission
Recent publications described that influenza Vaxinano's vaccine administered via a spray by the nasal route allows strong T-cell activation and production of sIgA in the mucosa (
Bernasconi V. & al., Front. Immunol. 2018). In this new publication (
Le MQ. & al., Int. J. Pharm. 2020) we demonstrated that Vaxinano's vaccine also inhibits the transmission of the viral infection.
These results are of main importance in the global context of the Covid-19 since the Vaxinano's technology is ready to be transposed to this very infectious coronavirus.
Vaxinano is starting collaborations on the rapid development of an anti-Covid-19 vaccine. New collaborators are welcome to contact us.
For more information: Le MQ. & al., Effective Nanoparticle-Based Nasal Vaccine against Latent and Congenital Toxoplasmosis in Sheep.
Front. Immunol. 2020.
Read the publication
